Suchergebnisse - "SARS-CoV2"

PubPharm (107.289)

101

Anti-spike antibody level is associated with the risk of clinical progression among subjects hospitalized with COVID-19 pneumonia : results from a retrospective cohort study

enthalten in: Infection | 2024

von Lapadula, G. | Mezzadri, L. | Lo Cascio, G. | +6

102

SARS-CoV-2 infection-induced immune thrombocytopenia : a systematic review of current reports

enthalten in: Annals of hematology | 2024

von Ono, R. | Kitagawa, I.

103

Role of the RAAS in mediating the pathophysiology of COVID-19

enthalten in: Pharmacological reports : PR | 2024

von Jasiczek, J. | Doroszko, A. | Trocha, T. | +1

104

Deciphering the similarities and disparities of molecular mechanisms behind respiratory epithelium response to HCoV-229E and SARS-CoV-2 and drug repurposing, a systems biology approach

enthalten in: Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences | 2024

von Dehghan, Z. | Mirmotalebisohi, S. | Mozafar, M. | +6

105

Simultaneous occurrence of autoimmune hepatitis and autoimmune hemolytic anemia after COVID-19 infection : case report and literature review

enthalten in: Clinical journal of gastroenterology | 2024

von Abe, R. | Hasegawa, N. | Suzuki, S. | +7

106

The impact of face coverings on audio-visual contributions to communication with conversational speech

enthalten in: Cognitive research: principles and implications | 2024

von Jackson, I. | Perugia, E. | Stone, M. | +1

107

Magnesium and vitamin D in long COVID syndrome; do they help?

enthalten in: Magnesium research | 2024

von Wolf, F. | Trapani, V.

108

COVID-19 Australia : Epidemiology Report 85: Reporting period ending 10 March 2024

enthalten in: Communicable diseases intelligence (2018) | 2024

von Viral Respiratory Diseases Epidemiology and Surveillance Team

109

COVID-19 Australia : Epidemiology Report 84: Reporting period ending 11 February 2024

enthalten in: Communicable diseases intelligence (2018) | 2024

von Viral Respiratory Diseases Epidemiology and Surveillance Team

110

Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023 : A VEBIS-EHR Network Study

enthalten in: Influenza and other respiratory viruses | 2024

von Monge, S. | Humphreys, J. | Nicolay, N. | +19